Drugs / Human immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07410039 Comparator | Feb 2026 → Jun 2027 expected | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human immunoglobulin | “Human immunoglobulin addition treatment group: IVIG + IVMP” NCT07410039 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07410039 ↗ |
| Modality | Protein / enzyme biologic | “Human immunoglobulin addition treatment group” NCT07410039 ↗ |